Michael D. West, Ph.D.
Chief Executive Officer
Michael D. West, Ph.D. has been Chief Executive Officer of OrthoCyte Corporation, a division of BioTime, Inc. since June 2010. He is a pioneer in the field of stem cell research and has extensive academic and business experience in age-related degenerative diseases, telomerase molecular biology and human embryonic stem cell research and development. Prior to joining BioTime, Dr. West served as President and Chief Scientific Officer of Advanced Cell Technology, Inc, a company engaged in developing human stem cell technology for use in regenerative medicine. Dr. West also founded Geron Corporation where he initiated and managed programs in telomerase diagnostics, oligonucleotide-based telomerase inhibition as anti-tumor therapy, and the cloning and use of telomerase in telomerase-mediated therapy wherein telomerase is utilized to immortalize human cells, and he initiated and managed the original collaborative effort that led to the first isolation of human embryonic stem and embryonic germ cells. Dr. West is an inventor named on over 60 patents and patent applications in the field of biotechnology and also serves as an Adjunct Professor of Bioengineering at the University of California, Berkeley. He has served on the BioTime Board of Directors since 2002. Dr. West received a B.S. Degree from Rensselaer Polytechnic Institute in 1976, an M.S. Degree in Biology from Andrews University in 1982, and a Ph.D. from Baylor College of Medicine in 1989 concentrating on the biology of cellular aging.
Francois Binette Ph.D.
Head of Global Development
Dr. François Binette is Head of Global Development, and head of OrthoCyte Corp, the orthopedic subsidiary of Biotime Inc. Dr. Binette has over 20 years of experience driving innovation in regenerative medicine therapy development with a focus in orthopedics. During his first industry appointment at Genzyme Tissue Repair in Cambridge, he helped pioneer Carticel™ for cartilage repair, the first FDA BLA-approved cell therapy product for human use. He then led R&D for Biosyntech, a startup biomaterials company in Montreal applying its proprietary platform for various tissue engineering and drug delivery applications. His systematic approach to demonstrating proof of principle in various indications brought numerous corporate partnership deals helping Biosyntech through a public offering. Dr. Binette was then joined Johnson and Johnson where he oversaw the DePuy Franchise, the second largest orthopedic business worldwide. Dr. Binette led several innovative regenerative medicine combination product development initiatives from bench top to approved clinical trials in US and Europe. Following JNJ, Dr. Binette joined the Spinal and Biologics business unit of Medtronic, the world’s largest medical device company, after which he founded Rediens Inc, a spine therapy start up company in California. Dr Binette received his PhD from Laval University in Québec City, followed with post-doctoral training at the Sanford-Burnham institute in La Jolla, and Harvard Medical School in Boston.